Ultragenyx Pharmaceutical Inc
Price
FilingsNewest: 8-K, Other eventsSep 17 →InsidersNo open-market buys. 9 insiders sold $3.6M, 11 of 23 sales on a 10b5-1 plan.→HoldersBlackRock 10.8%RTW Investments 7.9%Vanguard Portfolio 6.9%→PeersClosest companies: RCKT, SRPT, IRD→
From the filings
Figures
- Revenue
- $717.2Mlast 12 months
- Net income
- −$586.0Mlast 12 months
- Operating cash flow
- −$497.0Mlast 12 months
- Cash and equivalents
- $125.0Mat the last balance sheet
- Shares outstanding
- 98.6M shareson issue